KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to $690.0 million.

  • Teva Pharmaceutical Industries' Income from Continuing Operations rose 35090.91% to $690.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.6 billion, marking a year-over-year increase of 25834.15%. This contributed to the annual value of $1.4 billion for FY2025, which is 17158.16% up from last year.
  • As of Q4 2025, Teva Pharmaceutical Industries' Income from Continuing Operations stood at $690.0 million, which was up 35090.91% from $432.0 million recorded in Q3 2025.
  • In the past 5 years, Teva Pharmaceutical Industries' Income from Continuing Operations registered a high of $690.0 million during Q4 2025, and its lowest value of -$1.8 billion during Q4 2023.
  • Moreover, its 5-year median value for Income from Continuing Operations was -$43.5 million (2021), whereas its average is -$217.8 million.
  • As far as peak fluctuations go, Teva Pharmaceutical Industries' Income from Continuing Operations tumbled by 128658.54% in 2022, and later skyrocketed by 35090.91% in 2025.
  • Over the past 5 years, Teva Pharmaceutical Industries' Income from Continuing Operations (Quarter) stood at -$151.0 million in 2021, then plummeted by 783.44% to -$1.3 billion in 2022, then crashed by 34.63% to -$1.8 billion in 2023, then soared by 84.69% to -$275.0 million in 2024, then surged by 350.91% to $690.0 million in 2025.
  • Its last three reported values are $690.0 million in Q4 2025, $432.0 million for Q3 2025, and $281.0 million during Q2 2025.